Sodium–Glucose Cotransporter 2 Inhibitors, Glucagon-Like Peptide 1 Receptor Agonists, and Frailty Progression in Older Adults With Type 2 Diabetes
GLP-1RAs and SGLT-2is may slow frailty progression through mechanisms independent of cardiovascular benefits. Future trials should confirm these preliminary findings.
Authors
- Gahee Oh (ORCID: https://orcid.org/0000-0002-1598-4693)
- Saran Thanapluetiwong (ORCID: https://orcid.org/0000-0001-7832-7255)
- Dae Hyun Kim (ORCID: https://orcid.org/0000-0001-7290-6838)
- Chan Mi Park (ORCID: https://orcid.org/0000-0003-1880-048X)
- Darae Ko (ORCID: https://orcid.org/0000-0002-1174-7535)
- Xiaojun Chen (ORCID: https://orcid.org/0000-0002-0298-4491)
Institutions
- Beth Israel Deaconess Medical Center (US)
- Harvard University (US)
- Hebrew SeniorLife (US)
- Ramathibodi Hospital (TH)
Publication Details
- Journal
- Diabetes Care
- Published
- 2025-11-13
- DOI
- https://doi.org/10.2337/dc25-1031
- Citations
- 2
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 2.59